Is Pulmatrix, Inc. overvalued or undervalued?

As of 5 August 2019, Pulmatrix, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently overvalued based on its financial metrics. The Price to Book Value stands at 4.54, while the EV to Sales ratio is significantly high at 12.89. Additionally, the ROE is alarmingly negative at -170.58%, indicating severe profitability issues.
In comparison to its peers, Pulmatrix's EV to EBITDA ratio is -2.59, which is worse than Lexaria Bioscience Corp. at -1.4100 and Cyclerion Therapeutics, Inc. at -1.8268. This suggests that Pulmatrix is not only struggling relative to its industry but also reflects a concerning trend in its valuation. Despite a notable 1-year stock return of 248.99%, the overall financial health and valuation metrics indicate that Pulmatrix, Inc. is overvalued in the current market.